A review of successful flavivirus vaccines and the problems with those flaviviruses for which vaccines are not yet available

Vaccine

Volumn 32, Issue 12, 2014, Pages 1326-1337

  Ishikawa, Tomohiro ^a   Yamanaka, Atsushi ^b,c   Konishi, Eiji ^b,c  

^a DOKKYO MEDICAL UNIVERSITY   (Japan)

^b MAHIDOL UNIVERSITY   (Thailand)

^c OSAKA UNIVERSITY   (Japan)

Author keywords

Dengue; Japanese encephalitis; Tick borne encephalitis; Vaccine; West Nile fever; Yellow fever

Indexed keywords

DENGUE; JAPANESE ENCEPHALITIS; TICK-BORNE ENCEPHALITIS; VACCINE; WEST NILE FEVER; YELLOW FEVER;

ANIMALS; DENGUE; DENGUE VACCINES; DISEASE VECTORS; ENCEPHALITIS, JAPANESE; ENCEPHALITIS, TICK-BORNE; FLAVIVIRUS INFECTIONS; HUMANS; JAPANESE ENCEPHALITIS VACCINES; VIRAL VACCINES; WEST NILE FEVER; WEST NILE VIRUS VACCINES; YELLOW FEVER; YELLOW FEVER VACCINE;

EID: 84894437434     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.01.040     Document Type: Review

References (123)

1. Lindenbach B.D., Murray C., Thiel H.J., Rice C.M. Flaviviridae. Fields virology 2013, 712-746. Lippincott Williams & Wilkins, Philadelphia. sixth ed. D.M. Knipe, P.M. Howley (Eds.).
2. Sips G.J., Wilschut J., Smit J.M. Neuroinvasive flavivirus infections. Rev Med Virol 2012, 22:69-87.
3. Barrett A.D. Current status of flavivirus vaccines. Ann N Y Acad Sci 2001, 951:262-271.
4. Patel J.R., Heldens J.G. Immunoprophylaxis against important virus disease of horses, farm animals and birds. Vaccine 2009, 27:1797-1810.
5. Jentes E.S., Poumerol G., Gershman M.D., Hill D.R., Lemarchand J., Lewis R.F., et al. The revised global yellow fever risk map and recommendations for vaccination, 2010: consensus of the Informal WHO Working Group on Geographic Risk for Yellow Fever. Lancet Infect Dis 2011, 11:622-632.
6. Quaresma J.A., Pagliari C., Medeiros D.B., Duarte M.I., Vasconcelos P.F. Immunity and immune response, pathology and pathologic changes: progress and challenges in the immunopathology of yellow fever. Rev Med Virol 2013, 23:305-318.
7. World Health Organization. WHO Division of Epidemiological Surveillance and Health Situation Trend Assessment Global Health Situation and Projections-Estimates. Geneva, Switzerland; 1992.
8. Staples J.E., Monath T.P. Yellow fever: 100 years of discovery. JAMA 2008, 300:960-962.
9. Frierson J.G. The yellow fever vaccine: a history. Yale J Biol Med 2010, 83:77-85.
10. Theiler M., Smith H.H. The use of yellow fever virus modified by in vitro cultivation for human immunization. J Exp Med 1937, 65:787-800.
11. World Health Organization. Yellow Fever Initiative, Providing an opportunity of a lifetime. YFIbrochure. Available at. http://www.who.int/csr/disease/yellowfev/YFIbrochure.pdf.
12. Camacho L.A., Freire Mda S., Leal Mda L., Aguiar S.G., Nascimento J.P., Iguchi T., et al. Immunogenicity of WHO-17D and Brazilian 17DD yellow fever vaccines: a randomized trial. Rev Saude Publica 2004, 38:671-678.
13. Lang J., Zuckerman J., Clarke P., Barrett P., Kirkpatrick C., Blondeau C. Comparison of the immunogenicity and safety of two 17D yellow fever vaccines. Am J Trop Med Hyg 1999, 60:1045-1050.
14. Mason R.A., Tauraso N.M., Spertzel R.O., Ginn R.K. Yellow fever vaccine: direct challenge of monkeys given graded doses of 17D vaccine. Appl Microbiol 1973, 25:539-544.
15. Gotuzzo E., Yactayo S., Cordova E. Efficacy and duration of immunity after yellow fever vaccination: systematic review on the need for a booster every 10 years. Am J Trop Med Hyg 2013, 89:434-444.
16. Poland J.D., Calisher C.H., Monath T.P., Downs W.G., Murphy K. Persistence of neutralizing antibody 30-35 years after immunization with 17D yellow fever vaccine. Bull World Health Organ 1981, 59:895-900.
17. Tomori O. Yellow fever in Africa: public health impact and prospects for control in the 21st century. Biomedica 2002, 22:178-210.
18. Lindsey N.P., Schroeder B.A., Miller E.R., Braun M.M., Hinckley A.F., Marano N., et al. Adverse event reports following yellow fever vaccination. Vaccine 2008, 26:6077-6082.
19. Vasconcelos P.F., Luna E.J., Galler R., Silva L.J., Coimbra T.L., Barros V.L., et al. Serious adverse events associated with yellow fever 17DD vaccine in Brazil: a report of two cases. Lancet 2001, 358:91-97.
20. Martin M., Tsai T.F., Cropp B., Chang G.J., Holmes D.A., Tseng J., et al. Fever and multisystem organ failure associated with 17D-204 yellow fever vaccination: a report of four cases. Lancet 2001, 358:98-104.
21. Chan R.C., Penney D.J., Little D., Carter I.W., Roberts J.A., Rawlinson W.D. Hepatitis and death following vaccination with 17D-204 yellow fever vaccine. Lancet 2001, 358:121-122.
22. Thomas R.E., Lorenzetti D.L., Spragins W., Jackson D., Williamson T. Active and passive surveillance of yellow fever vaccine 17D or 17DD-associated serious adverse events: systematic review. Vaccine 2011, 29:4544-4555.
23. Khromava A.Y., Eidex R.B., Weld L.H., Kohl K.S., Bradshaw R.D., Chen R.T., et al. Yellow fever vaccine: an updated assessment of advanced age as a risk factor for serious adverse events. Vaccine 2005, 23:3256-3263.
24. Breugelmans J.G., Lewis R.F., Agbenu E., Veit O., Jackson D., Domingo C., et al. Adverse events following yellow fever preventive vaccination campaigns in eight African countries from 2007 to 2010. Vaccine 2013, 31:1819-1829.
25. Monath T.P., Fowler E., Johnson C.T., Balser J., Morin M.J., Sisti M., et al. An inactivated cell-culture vaccine against yellow fever. N Engl J Med 2011, 364:1326-1333.
26. Scherer W.F., Moyer J.T., Izumi T., Gresser I., McCown J. Ecologic studies of Japanese encephalitis virus in Japan. VI. Swine infection. Am J Trop Med Hyg 1959, 8:698-706.
27. van den Hurk A.F., Ritchie S.A., Mackenzie J.S. Ecology and geographical expansion of Japanese encephalitis virus. Annu Rev Entomol 2009, 54:17-35.
28. Erlanger T.E., Weiss S., Keiser J., Utzinger J., Wiedenmayer K. Past, present, and future of Japanese encephalitis. Emerg Infect Dis 2009, 15:1-7.
29. Ishikawa T., Konishi E. Combating Japanese encephalitis: Vero-cell derived inactivated vaccines and the situation in Japan. Future Virol 2010, 5:785-799.
30. Campbell G.L., Hills S.L., Fischer M., Jacobson J.A., Hoke C.H., Hombach J.M., et al. Estimated global incidence of Japanese encephalitis: a systematic review. Bull World Health Organ 2011, 89:766-774. 774A-E.
31. Hombach J., Solomon T., Kurane I., Jacobson J., Wood D. Report on a WHO consultation on immunological endpoints for evaluation of new Japanese encephalitis vaccines, WHO, Geneva, 2-3 September, 2004. Vaccine 2005, 23:5205-5211.
32. Hsu T.C., Chow L.P., Wei H.Y., Chen C.L., Hsu S.T. A controlled field trial for an evaluation of effectiveness of mouse-brain Japanese encephalitis vaccine. Taiwan Yi Xue Hui Za Zhi 1971, 70:55-62.
33. Hoke C.H., Nisalak A., Sangawhipa N., Jatanasen S., Laorakapongse T., Innis B.L., et al. Protection against Japanese encephalitis by inactivated vaccines. N Engl J Med 1988, 319:608-614.
34. Japanese encephalitis surveillance and immunization - Asia and the Western pacific, 2012. MMWR Morb Mortal Wkly Rep 2013, 62:658-662.
35. Arai S., Matsunaga Y., Takasaki T., Tanaka-Taya K., Taniguchi K., Okabe N., et al. Japanese encephalitis: surveillance and elimination effort in Japan from 1982 to 2004. Jpn J Infect Dis 2008, 61:333-338.
36. Kim H.C., Turell M.J., O'Guinn M.L., Lee J.S., Chong S.T., Ju Y.R., et al. Historical review and surveillance of Japanese encephalitis, Republic of Korea, 2002-2004. Entomol Res 2007, 37:267-274.
37. Wu Y.C., Huang Y.S., Chien L.J., Lin T.L., Yueh Y.Y., Tseng W.L., et al. The epidemiology of Japanese encephalitis on Taiwan during 1966-1997. Am J Trop Med Hyg 1999, 61:78-84.
38. Tauber E., Kollaritsch H., Korinek M., Rendi-Wagner P., Jilma B., Firbas C., et al. Safety and immunogenicity of a Vero-cell-derived, inactivated Japanese encephalitis vaccine: a non-inferiority, phase III, randomised controlled trial. Lancet 2007, 370:1847-1853.
39. Schuller E., Jilma B., Voicu V., Golor G., Kollaritsch H., Kaltenbock A., et al. Long-term immunogenicity of the new Vero cell-derived, inactivated Japanese encephalitis virus vaccine IC51 Six and 12 month results of a multicenter follow-up phase 3 study. Vaccine 2008, 26:4382-4386.
40. Schuller E., Klade C.S., Wolfl G., Kaltenbock A., Dewasthaly S., Tauber E. Comparison of a single, high-dose vaccination regimen to the standard regimen for the investigational Japanese encephalitis vaccine, IC51: a randomized, observer-blind, controlled Phase 3 study. Vaccine 2009, 27:2188-2193.
41. Schuller E., Klingler A., Dubischar-Kastner K., Dewasthaly S., Muller Z. Safety profile of the Vero cell-derived Japanese encephalitis virus (JEV) vaccine IXIARO((R)). Vaccine 2011, 29:8669-8676.
42. Kaltenbock A., Dubischar-Kastner K., Schuller E., Datla M., Klade C.S., Kishore T.S. Immunogenicity and safety of IXIARO((R)) (IC51) in a Phase II study in healthy Indian children between 1 and 3 years of age. Vaccine 2010, 28:834-839.
43. Kikukawa A., Gomi Y., Akechi M., Onishi T., Manabe S., Namazue J., et al. Superior immunogenicity of a freeze-dried, cell culture-derived Japanese encephalitis vaccine (inactivated). Vaccine 2012, 30:2329-2335.
44. Okada K., Iwasa T., Namazue J., Akechi M., Ueda S. Safety and immunogenicity of a freeze-dried, cell culture-derived Japanese encephalitis vaccine (Inactivated) (JEBIK((R))V) in children. Vaccine 2012, 30:5967-5972.
45. Kuzuhara S., Nakamura H., Hayashida K., Obata J., Abe M., Sonoda K., et al. Non-clinical and phase I clinical trials of a Vero cell-derived inactivated Japanese encephalitis vaccine. Vaccine 2003, 21(31):4519-4526.
46. Beasley D.W., Lewthwaite P., Solomon T. Current use and development of vaccines for Japanese encephalitis. Expert Opin Biol Ther 2008, 8:95-106.
47. Tsai T.F. New initiatives for the control of Japanese encephalitis by vaccination: minutes of a WHO/CVI meeting, Bangkok, Thailand, 13-15 October 1998. Vaccine 2000, 18(Suppl. 2):1-25.
48. The 63rd WHO Expert Committee on Biological Standardization. Recommendations to assure the quality, safety and efficacy of Japanese encephalitis vaccine (live, attenuated) for human use 2012, Available at: http://www.who.int/biologicals/vaccines/WHO_BS_2012_JE_LA_DB_4March2012.pdf; http://www.who.int/biolo.
49. Guy B., Guirakhoo F., Barban V., Higgs S., Monath T.P., Lang J. Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue. West Nile and Japanese encephalitis viruses. Vaccine 2010, 28:632-649.
50. Chokephaibulkit K., Sirivichayakul C., Thisyakorn U., Sabchareon A., Pancharoen C., Bouckenooghe A., et al. Safety and immunogenicity of a single administration of live-attenuated Japanese encephalitis vaccine in previously primed 2- to 5-year-olds and naive 12- to 24-month-olds: multicenter randomized controlled trial. Pediatr Infect Dis J 2010, 29:1111-1117.
51. Torresi J., McCarthy K., Feroldi E., Meric C. Immunogenicity, safety and tolerability in adults of a new single-dose, live-attenuated vaccine against Japanese encephalitis: randomised controlled phase 3 trials. Vaccine 2010, 28:7993-8000.
52. Feroldi E., Pancharoen C., Kosalaraksa P., Watanaveeradej V., Phirangkul K., Capeding M.R., et al. Single-dose, live-attenuated Japanese encephalitis vaccine in children aged 12-18 months: randomized, controlled phase 3 immunogenicity and safety trial. Hum Vaccin Immunother 2012, 8:929-937.
53. Pan X.L., Liu H., Wang H.Y., Fu S.H., Liu H.Z., Zhang H.L., et al. Emergence of genotype I of Japanese encephalitis virus as the dominant genotype in Asia. J Virol 2011, 85:9847-9853.
54. Erra E.O., Askling H.H., Yoksan S., Rombo L., Riutta J., Vene S., et al. Cross-protective capacity of Japanese encephalitis (JE) vaccines against circulating heterologous JE virus genotypes. Clin Infect Dis 2013, 56:267-270.
55. Amicizia D., Domnich A., Panatto D., Lai P.L., Cristina M.L., Avio U., et al. Epidemiology of tick-borne encephalitis (TBE) in Europe and its prevention by available vaccines. Hum Vaccin Immunother 2013, 9:1161-1169.
56. Mansfield K.L., Johnson N., Phipps L.P., Stephenson J.R., Fooks A.R., Solomon T. Tick-borne encephalitis virus - a review of an emerging zoonosis. J Gen Virol 2009, 90:1781-1794.
57. Vaccines against tick-borne encephalitis: WHO position paper. Wkly Epidemiol Rec 2011, 86:241-256.
58. Kunze U. Tick-borne encephalitis: the impact of epidemiology, changing lifestyle, and environmental factors. Conference report of the 12th Annual Meeting of the International Scientific Working Group on Tick-Borne Encephalitis (ISW-TBE). Vaccine 2011, 29:1355-1356.
59. Donoso Mantke O., Escadafal C., Niedrig M., Pfeffer M., Working Group For Tick-Borne Encephalitis Virus C Tick-borne encephalitis in Europe, 2007 to 2009. Euro Surveill 2011, 16. pii: 19976.
60. Marth E., Kleinhappl B. Albumin is a necessary stabilizer of TBE-vaccine to avoid fever in children after vaccination. Vaccine 2001, 20:532-537.
61. Demicheli V., Debalini M.G., Rivetti A. Vaccines for preventing tick-borne encephalitis. Cochrane Database Syst Rev 2009, 21. CD000977.
62. Loew-Baselli A., Poellabauer E.M., Pavlova B.G., Fritsch S., Firth C., Petermann R., et al. Prevention of tick-borne encephalitis by FSME-IMMUN vaccines: review of a clinical development programme. Vaccine 2011, 29:7307-7319.
63. Zent O., Banzhoff A., Hilbert A.K., Meriste S., Sluzewski W., Wittermann Ch. Safety, immunogenicity and tolerability of a new pediatric tick-borne encephalitis (TBE) vaccine, free of protein-derived stabilizer. Vaccine 2003, 21:3584-3592.
64. Zent O., Beran J., Jilg W., Mach T., Banzhoff A. Clinical evaluation of a polygeline-free tick-borne encephalitis vaccine for adolescents and adults. Vaccine 2003, 21:738-741.
65. Plentz A., Jilg W., Schwarz T.F., Kuhr H.B., Zent O. Long-term persistence of tick-borne encephalitis antibodies in adults 5 years after booster vaccination with Encepur Adults. Vaccine 2009, 27:853-856.
66. Wittermann C., Petri E., Zent O. Long-term persistence of tick-borne encephalitis antibodies in children 5 years after first booster vaccination with Encepur Children. Vaccine 2009, 27:1585-1588.
67. Leonova G.N., Pavlenko E.V. Characterization of neutralizing antibodies to Far Eastern of tick-borne encephalitis virus subtype and the antibody avidity for four tick-borne encephalitis vaccines in human. Vaccine 2009, 27:2899-2904.
68. Heinz F.X., Stiasny K., Holzmann H., Grgic-Vitek M., Kriz B., Essl A., et al. Vaccination and tick-borne encephalitis, central Europe. Emerg Infect Dis 2013, 19:69-76.
69. Fritz R., Orlinger K.K., Hofmeister Y., Janecki K., Traweger A., Perez-Burgos L., et al. Quantitative comparison of the cross-protection induced by tick-borne encephalitis virus vaccines based on European and Far Eastern virus subtypes. Vaccine 2012, 30:1165-1169.
70. Orlinger K.K., Hofmeister Y., Fritz R., Holzer G.W., Falkner F.G., Unger B., et al. A tick-borne encephalitis virus vaccine based on the European prototype strain induces broadly reactive cross-neutralizing antibodies in humans. J Infect Dis 2011, 203:1556-1564.
71. Halstead S.B. Dengue. Lancet 2007, 370:1644-1652.
72. Vasilakis N., Cardosa J., Hanley K.A., Holmes E.C., Weaver S.C. Fever from the forest: prospects for the continued emergence of sylvatic dengue virus and its impact on public health. Nat Rev Microbiol 2011, 9:532-541.
73. Gubler D.J. Dengue and dengue hemorrhagic fever. Clin Microbiol Rev 1998, 11:480-496.
74. Bhatt S., Gething P.W., Brady O.J., Messina J.P., Farlow A.W., Moyes C.L., et al. The global distribution and burden of dengue. Nature 2013, 496:504-507.
75. Rothman A.L. Cellular immunology of sequential dengue virus infection and its role in disease pathogenesis. Curr Top Microbiol Immunol 2010, 338:83-98.
76. Vaughn D.W., Green S., Kalayanarooj S., Innis B.L., Nimmannitya S., Suntayakorn S., et al. Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J Infect Dis 2000, 181:2-9.
77. Halstead S.B. Neutralization and antibody-dependent enhancement of dengue viruses. Adv Virus Res 2003, 60:421-467.
78. Sabin A.B. Research on dengue during World War II. Am J Trop Med Hyg 1952, 1:30-50.
79. Halstead S.B. Immune enhancement of viral infection. Prog Allergy 1982, 31:301-364.
80. Hombach J., Cardosa M.J., Sabchareon A., Vaughn D.W., Barrett A.D. Scientific consultation on immunological correlates of protection induced by dengue vaccines report from a meeting held at the World Health Organization 17-18 November 2005. Vaccine 2007, 25:4130-4139.
81. Sabchareon A., Lang J., Chanthavanich P., Yoksan S., Forrat R., Attanath P., et al. Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers: role of serotype concentration, ratio, and multiple doses. Am J Trop Med Hyg 2002, 66:264-272.
82. Sun W., Edelman R., Kanesa-Thasan N., Eckels K.H., Putnak J.R., King A.D., et al. Vaccination of human volunteers with monovalent and tetravalent live-attenuated dengue vaccine candidates. Am J Trop Med Hyg 2003, 69:24-31.
83. Sun W., Cunningham D., Wasserman S.S., Perry J., Putnak J.R., Eckels K.H., et al. Phase 2 clinical trial of three formulations of tetravalent live-attenuated dengue vaccine in flavivirus-naive adults. Hum Vaccine 2009, 5:33-40.
84. Stephenson J.R. Understanding dengue pathogenesis: implications for vaccine design. Bull World Health Organ 2005, 83:308-314.
85. Kitchener S., Nissen M., Nasveld P., Forrat R., Yoksan S., Lang J., et al. Immunogenicity and safety of two live-attenuated tetravalent dengue vaccine formulations in healthy Australian adults. Vaccine 2006, 24:1238-1241.
86. Thomas S.J., Eckels K.H., Carletti I., De La Barrera R., Dessy F., Fernandez S., et al. A phase II, randomized, safety and immunogenicity study of a re-derived, live-attenuated dengue virus vaccine in healthy adults. Am J Trop Med Hyg 2013, 88:73-88.
87. Morrison D., Legg T.J., Billings C.W., Forrat R., Yoksan S., Lang J. A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavivirus-naive adults. J Infect Dis 2010, 201:370-377.
88. Sabchareon A., Wallace D., Sirivichayakul C., Limkittikul K., Chanthavanich P., Suvannadabba S., et al. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet 2012, 380:1559-1567.
89. Osorio J.E., Huang C.Y., Kinney R.M., Stinchcomb D.T. Development of DENVax: a chimeric dengue-2 PDK-53-based tetravalent vaccine for protection against dengue fever. Vaccine 2011, 29:7251-7260.
90. Durbin A.P., Kirkpatrick B.D., Pierce K.K., Schmidt A.C., Whitehead S.S. Development and clinical evaluation of multiple investigational monovalent DENV vaccines to identify components for inclusion in a live attenuated tetravalent DENV vaccine. Vaccine 2011, 29:7242-7250.
91. Lindow J.C., Durbin A.P., Whitehead S.S., Pierce K.K., Carmolli M.P., Kirkpatrick B.D. Vaccination of volunteers with low-dose, live-attenuated, dengue viruses leads to serotype-specific immunologic and virologic profiles. Vaccine 2013, 31:3347-3352.
92. Durbin A.P., Kirkpatrick B.D., Pierce K.K., Elwood D., Larsson C.J., Lindow J.C., et al. A single dose of any of four different live attenuated tetravalent dengue vaccines is safe and immunogenic in flavivirus-naive adults: a randomized, double-blind clinical trial. J Infect Dis 2013, 207:957-965.
93. Coller B.A., Clements D.E., Bett A.J., Sagar S.L., Ter Meulen J.H. The development of recombinant subunit envelope-based vaccines to protect against dengue virus induced disease. Vaccine 2011, 29:7267-7275.
94. World Health Organization. Dengue Vaccine Initiative, Subunit, Inactivated Vaccines & DNA Vaccines. Available at. http://www.denguevaccines.org/subunit-and-inactivated-vaccines.
95. Beckett C.G., Tjaden J., Burgess T., Danko J.R., Tamminga C., Simmons M., et al. Evaluation of a prototype dengue-1 DNA vaccine in a Phase 1 clinical trial. Vaccine 2011, 29:960-968.
96. Porter K.R., Ewing D., Chen L., Wu S.J., Hayes C.G., Ferrari M., et al. Immunogenicity and protective efficacy of a vaxfectin-adjuvanted tetravalent dengue DNA vaccine. Vaccine 2012, 30:336-341.
97. Arya V. An effective dengue vaccine: a glass half full or half empty. Natl Med J India 2013, 26:38-39.
98. Halstead S.B. Dengue vaccine development: a 75% solution. Lancet 2012, 380:1535-1536.
99. Swaminathan S., Khanna N., Herring B., Mahalingam S. Dengue vaccine efficacy trial: does interference cause failure. Lancet Infect Dis 2013, 13:191-192.
100. Rodriguez-Barraquer I., Mier-Y-Teran-Romero L., Burke D.S., Cummings D.A. Challenges in the interpretation of dengue vaccine trial results. PLoS Negl Trop Dis 2013, 7:e2126.
101. Questions and Answers on Dengue Vaccines: Phase IIb study of CYD-TDV. Available at. http://www.who.int/immunization/research/committees/WHO_dengue_vaccine_QA_september2012.pdf.
102. Hss A.S., Koh M.T., Tan K.K., Chan L.G., Zhou L., Bouckenooghe A., et al. Safety and immunogenicity of a tetravalent dengue vaccine in healthy children aged 2-11 years in Malaysia: a randomized, placebo-controlled, Phase III study. Vaccine 2013, 31:5814-5821.
103. Rodrigo W.W., Alcena D.C., Rose R.C., Jin X., Schlesinger J.J. An automated Dengue virus microneutralization plaque assay performed in human Fc{gamma} receptor-expressing CV-1 cells. Am J Trop Med Hyg 2009, 80:61-65.
104. Moi M.L., Lim C.K., Chua K.B., Takasaki T., Kurane I. Dengue virus infection-enhancing activity in serum samples with neutralizing activity as determined by using FcgammaR-expressing cells. PLoS Negl Trop Dis 2012, 6:e1536.
105. Hughes H.R., Crill W.D., Chang G.J. Manipulation of immunodominant dengue virus E protein epitopes reduces potential antibody-dependent enhancement. Virol J 2012, 9:115.
106. Crill W.D., Hughes H.R., Trainor N.B., Davis B.S., Whitney M.T., Chang G.J. Sculpting humoral immunity through dengue vaccination to enhance protective immunity. Front Immunol 2012, 3:334.
107. Yauch L.E., Shresta S. Mouse models of dengue virus infection and disease. Antiviral Res 2008, 80:87-93.
108. Omatsu T., Moi M.L., Hirayama T., Takasaki T., Nakamura S., Tajima S., et al. Common marmoset (Callithrix jacchus) as a primate model of dengue virus infection: development of high levels of viraemia and demonstration of protective immunity. J Gen Virol 2011, 92:2272-2280.
109. Sun W., Eckels K.H., Putnak J.R., Lyons A.G., Thomas S.J., Vaughn D.W., et al. Experimental dengue virus challenge of human subjects previously vaccinated with live attenuated tetravalent dengue vaccines. J Infect Dis 2013, 207:700-708.
110. Durbin A.P., Whitehead S.S. The dengue human challenge model: has the time come to accept this challenge. J Infect Dis 2013, 207:697-699.
111. Rossi S.L., Ross T.M., Evans J.D. West Nile virus. Clin Lab Med 2010, 30:47-65.
112. Blitvich B.J. Transmission dynamics and changing epidemiology of West Nile virus. Anim Health Res Rev 2008, 9:71-86.
113. Mackenzie J.S., Williams D.T. The zoonotic flaviviruses of southern, south-eastern and eastern Asia, and Australasia: the potential for emergent viruses. Zoonoses Public Health 2009, 56:338-356.
114. Murray K.O., Walker C., Gould E. The virology, epidemiology, and clinical impact of West Nile virus: a decade of advancements in research since its introduction into the Western Hemisphere. Epidemiol Infect 2011, 139:807-817.
115. Lindsey N.P., Staples J.E., Lehman J.A., Fischer M. Surveillance for human West Nile virus disease - United States, 1999-2008. MMWR Surveill Summ 2010, 59:1-17.
116. Dauphin G., Zientara S. West Nile virus: recent trends in diagnosis and vaccine development. Vaccine 2007, 25:5563-5576.
117. De Filette M., Ulbert S., Diamond M., Sanders N.N. Recent progress in West Nile virus diagnosis and vaccination. Vet Res 2012, 43:16.
118. Biedenbender R., Bevilacqua J., Gregg A.M., Watson M., Dayan G. Phase II, randomized, double-blind, placebo-controlled, multicenter study to investigate the immunogenicity and safety of a West Nile virus vaccine in healthy adults. J Infect Dis 2011, 203:75-84.
119. Dayan G.H., Bevilacqua J., Coleman D., Buldo A., Risi G. Phase II, dose ranging study of the safety and immunogenicity of single dose West Nile vaccine in healthy adults ≥ 50 years of age. Vaccine 2012, 30:6656-6664.
120. Durbin A.P., Wright P.F., Cox A., Kagucia W., Elwood D., Henderson S., et al. The live attenuated chimeric vaccine rWN/DEN4Delta30 is well-tolerated and immunogenic in healthy flavivirus-naive adult volunteers. Vaccine 2013, 31:5772-5777.
121. Ledgerwood J.E., Pierson T.C., Hubka S.A., Desai N., Rucker S., Gordon I.J., et al. A West Nile virus DNA vaccine utilizing a modified promoter induces neutralizing antibody in younger and older healthy adults in a phase I clinical trial. J Infect Dis 2011, 203:1396-1404.
122. Lieberman M.M., Nerurkar V.R., Luo H., Cropp B., Carrion R., de la Garza M., et al. Immunogenicity and protective efficacy of a recombinant subunit West Nile virus vaccine in rhesus monkeys. Clin Vaccine Immunol 2009, 16:1332-1337.
123. Zohrabian A., Hayes E.B., Petersen L.R. Cost-effectiveness of West Nile virus vaccination. Emerg Infect Dis 2006, 12:375-380.